ÂÜÀòÂÒÂ×

Dr. Srinivas has over 30 years of experience in drug discovery and development with a focus on the areas of clinical pharmacology, PKPD, ADME, biopharmaceutics, bioanalysis, and drug delivery. Most recently, he was Vice President at Allucent, where he provided clinical pharmacology strategy for the small and large molecule/biosimilars development as well as 505(b)(2) clinical/regulatory strategy. Prior to Allucent, Dr. Srinivas worked in various companies, in positions of increasing responsibility, such as Bristol-Myers Squibb, Dr. Reddy’s laboratories, Eli Lilly’s JV, Zydus Cadila, and Jubilant. Dr. Srinivas has been involved across various stages of clinical development from Phase 1 to Phase 3 programs, and has supported several Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biologics License Applications (BLAs) filings. Dr. Srinivas holds a Doctorate in Pharmaceutical Sciences from the University of Saskatchewan, Canada. Dr. Srinivas has authored over 375 scientific publications and serves on the editorial board of several journals.